OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that it will reduce its work force by approximately 25% while retaining its revenue guidance ...

A co-development agreement for Locteron has been in place between OctoPlus and Biolex since 2005. Highly promising clinical trial results have been published during the collaboration so far and the ...

Indian generics maker Dr. Reddy's Laboratories ($RDY) will elevate its skills in manufacturing complex injectable drugs with a $35.7 million deal to buy Dutch CDMO ...

Jul 12, 2010 (Thomson Reuters ONE via COMTEX) -- OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that it has signed a pharmaceutical development and manufacturing ...

India-based pharmaceutical company, Dr Reddy’s Laboratories, has announced an intended public offer to acquire the issued and outstanding shares of OctoPlus NV for an offer price of EU €27.39 million ...

Dr Reddy's is planning to acquire the specialty injectable company OctoPlus for approximately EUR 27.4 million ($35.7 million) in cash to strengthen its technological capabilities in drug delivery. Dr ...

AMSTERDAM, Oct 6 (Reuters) - Dutch biotech firm OctoPlus said on Monday it had signed a licence and manufacturing deal for its lead product Locteron with Biolex Therapeutics worth up to 108 million ...

In a joint statement with OctoPlus, DRL said both the companies have reached conditional agreement in connection with an intended public offer by DRL or a wholly owned subsidiary of DRL. Chief ...

OctoPlus N.V. has announced that it has signed an exclusive license and product acquisition agreement to license its share of the commercial rights to its lead product Locteron® to co-development ...